FDA approves Oncomine Dx Target Test for RET fusion-positive NSCLC
Oncomine Dx Target Test was previously approved as a NGS-based CDx for biomarkers related to three NSCLC therapies
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 Sep 20
Oncomine Dx Target Test was previously approved as a NGS-based CDx for biomarkers related to three NSCLC therapies
09 Sep 20
New antibody test system provides results in 15 minutes from finger stick, venous whole blood, plasma, or serum…
09 Sep 20
Access Anti-SARS-CoV-2 Antigen Test, developed in collaboration with Ellume, is easy to use and provides accurate results in…
08 Sep 20
US FDA clearance for ender MASS, enabling on-site and pop-up labs to operate rapid testing for COVID-19, anticipated…
07 Sep 20
The Affimer-based ELISA laboratory test will facilitate efficient detection of the SARS-CoV-2 virus
07 Sep 20
Maxim Biomedical is focused on developing in-vitro diagnostic (IVD) and Point-of-Care (POC) testing solutions
07 Sep 20
The Australian government funding is expected to support the commercialisation of SpeeDx’ respiratory virus host response test, dubbed…
04 Sep 20
The Brevitest SARS-CoV-2 IgG Test detects the presence of SARS-CoV-2 specific IgG antibodies in plasma or serum using…
04 Sep 20
MiraDx will utilize ORAcollect·RNA to collect oropharyngeal samples in their COVID-19 testing program for essential workers and first…
03 Sep 20
Northwell Health has spent more than $30 million since the beginning of the pandemic on COVID-19 testing equipment…